<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01217762</url>
  </required_header>
  <id_info>
    <org_study_id>CLH001</org_study_id>
    <nct_id>NCT01217762</nct_id>
  </id_info>
  <brief_title>Safety &amp; Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Tolerability of the IRay Stereotactic Radiosurgery System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oraya Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oraya Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and clinical feasibility of the IRay
      System for the treatment of wet age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the safety and clinical feasibility of stereotactic
      radiotherapy with the Oraya IRay system for the treatment of choroidal neovascularization
      (CNV) associated with age-related macular degeneration (AMD), as measured by incidence and
      severity of ocular radiation related serious adverse events (SAE) and adverse events (AE) in
      subjects treated with an 11, 16 or 24 Gray (Gy) macular dose through the 60-month follow-up
      visit.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ocular radiation-related adverse events</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of ocular adverse events</measure>
    <time_frame>Through month 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who lose at least 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in best corrected visual acuity (BCVA)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects gaining ≥ 15 ETDRS letters</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects gaining ≥ 0 ETDRS letters</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in ETDRS visual acuity</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to anti-VEGF retreatment following 2nd mandatory injection (excluding radiation-first subjects)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean total number of ranibizumab injections</measure>
    <time_frame>Through month 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in choroidal neovascularization (CNV) size by fluorescein angiography (FA)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lesion size by fluorescein angiography (FA)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central retinal lesion thickness by optical coherence tomography (OCT)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central subfield thickness by optical coherence tomography (OCT)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Wet Age-Related Macular Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <condition>Eye Diseases</condition>
  <condition>Retinal Diseases</condition>
  <arm_group>
    <arm_group_label>11 Gy IRay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 Gy IRay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>16 Gy IRay - Radiation First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16 Gy IRay and Lucentis PRN (N = 13)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 Gy IRay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IRay</intervention_name>
    <description>Low voltage stereotactic radiotherapy system</description>
    <arm_group_label>11 Gy IRay</arm_group_label>
    <arm_group_label>16 Gy IRay</arm_group_label>
    <arm_group_label>16 Gy IRay - Radiation First</arm_group_label>
    <arm_group_label>24 Gy IRay</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be age 50 or older

          -  Women must be post-menopausal ≥1 year or surgically sterilized

          -  Subjects must have choroidal neovascularization lesion size of ≤11 total disc areas
             (28.26mm), and a greatest linear dimension of ≤6 mm

          -  Subjects must have Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected
             visual acuity of 69 to 24 letters (20/40 to 20/320 Snellen Equivalent) in the study
             eye

          -  Subretinal hemorrhage (if any) must not comprise more than 50% of total lesion size,
             and may not involve the subfoveal space

        Exclusion Criteria:

          -  Subjects with prior or concurrent therapies including submacular surgery, thermal
             laser photocoagulation (with or without photographic evidence), photodynamic therapy
             and transpupillary thermotherapy (TTT)

          -  Subjects with concomitant disease in the study eye, including uveitis, diabetic
             retinopathy,presence of RPE tears or rips, acute ocular or periocular infection

          -  Subjects with advanced glaucoma (&gt;0.8 cup to disk ratio) or intraocular pressure ≥30
             mmHg in the study eye

          -  Previous glaucoma filtering surgery in the study eye

          -  Refractive error in the study eye demonstrating more than -8 diopters of myopia (or
             globe axial length ≥26 mm). For subjects who have undergone prior refractive or
             cataract surgery in the study eye, the preoperative refractive error cannot exceed -8
             diopters of myopia

          -  Subjects with any retinal vasculopathies, including diabetic retinopathy, retinal vein
             occlusions, etc. in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis O'Shaughnessy, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Oraya Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociación Para Evitar la Ceguera en México, I.A.P.</name>
      <address>
        <city>Mexico Distrito Federal</city>
        <state>Delegación Coyoacán</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.orayainc.com/clinicaltrials.asp</url>
    <description>Click here to learn about this and other studies being conducted at Oraya Therapeutics, Inc.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2010</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oraya</keyword>
  <keyword>Oraya Therapeutics, Inc.</keyword>
  <keyword>low voltage stereotactic radiosurgery</keyword>
  <keyword>radiosurgery</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>IRay</keyword>
  <keyword>AMD</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Wet AMD</keyword>
  <keyword>xray</keyword>
  <keyword>radiation</keyword>
  <keyword>x ray</keyword>
  <keyword>external beam radiation</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Lucentis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

